Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

226 to 241 of 241 results

US FDA advisory panel votes against added indication for Bayer's Xarelto

24-05-2012

Despite relatively positive briefing papers earlier this week (The Pharma Letter May 22), the US Food…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

FDA staffers basically back Xarelto for ACS but identify missing data in study

22-05-2012

The US Food and Drug Administration advisory panelists due to revue Johnson & Johnson (NYSE: JNJ) and…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price

16-05-2012

UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini

15-05-2012

In a two part transaction, USA-based Furiex Pharmaceuticals (Nasdaq: FURX) has entered into an agreement…

ALZA CorpFuriex PharmaceuticalsJanssen PharmaceuticaJohnson & JohnsonLicensingMen's HealthMenariniPharmaceuticalPriligy

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

EU Commission OKs J&J's buy of Synthes, but with conditions

22-04-2012

The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat

18-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer

10-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) said on Monday that Sherilyn (Sheri) McCoy, vice chairman…

AstraZenecaJohnson & JohnsonManagementOptimer PharmaceuticalsPharmaceutical

Forest Labs buys Bystolic rights from Janssen for $357 million

03-04-2012

Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

226 to 241 of 241 results

Back to top